



PTO/SB/08A (04-07)

Approved for use through 09/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1

of 47

Application Number	09/904,356
Filing Date	July 12, 2001
First Named Inventor	G.P. Allaway et al.
Art Unit	1968
Examiner Name	Jeffery S. Parkin
Attorney Docket Number	43966-CB

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US- 6,258,527	07-10-2001	Littman	
		US- 6,258,782	07-10-2001	Barney et al.	
		US- 6,265,184	07-24-2001	Gary	
		US- 6,268,477	06-31-2002	Gary	
		US- 6,448,375	09-10-2002	Samson	
		US- 6,692,745	02-17-2004	Olson	
		US- 6,692,938	02-17-2004	Samson	
		US- 6,797,811	09-28-2004	Gary	
		US- 6,972,126	12-06-2005	Allaway	
		US- 6,800,447	10-05-2004	Samson	
		US- 5,939,320	08-17-1999	Littman	
		US- 5,817,767	10-06-1998	Allaway	
		US- 6,100,087	08-08-2000	J. Rossi et al.	
		US- 7,175,988	02-13-2003	V. Roschke et al.	
		US- 6,528,625	03-04-2003	L. Wu	
		US- 6,548,636	04-15-2003	T. Dragic	
		US- 7,118,859	10-10-2006	V.M. Litwin et al.	
		US- 7,138,119	11-21-2006	W.C Olson et al.	
		US- 6,930,174	08-16-2005	M. Samson et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ *Number ⁴ *Kind Code ⁵ (if known)	MM-DD-YYYY			
		WO 97/37005	10-27-1997			
		WO 97/28258	08-07-1997			
		WO 97/44462	11-27-1997			
		WO 01/64710	09-07-2001			
		WO 02/068608	09-06-2002			
		WO 02/083172	10-24-2002			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Applicants: G.P. Allaway et al.
Serial No.: 09/904,356
Filed: July, 12, 2001
Exhibit A

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 47**Complete if Known**

Application Number	09/904,356
Filing Date	July 12, 2001
First Named Inventor	G.P. Allaway et al.
Art Unit	1968
Examiner Name	Jeffery S. Parkin
Attorney Docket Number	43966-CB

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US- 7,151,087 B2	12-19-2006	C. Combadiere et al.	
		US- 7,129,055	10-31-2006	D. Littman et al.	
		US- 7,060,273	06-13-2006	W.C. Olson et al.	
		US- 7,122,185	10-17-2006	W.C. Olson et al.	
		US- 6,908,734	06-21-2005	T. Dragic et al.	
		US- 2002-0068813 A1	06-06-2002	T. Dragic et al.	
		US- 2004-0161739	08-19-2004	M. Samson et al.	
		US- 2004-0110127	06-10-2004	M. Samson et al.	
		US- 2005-0154193	07-14-2005	V. Roschke	
		US- 2003-0166024	09-04-2003	C. Rosen et al.	
		US- 2002-0048786	04-25-2002	C. Rosen et al.	
		US- 2002-0061834	05-23-2002	C. Rosen et al.	
		US- 2003-0166870	12-23-2004	L. Wu et al.	
		US- 2003-0195348	10-16-2003	C. Combadiere	
		US- 2003-0003440	01-02-2003	L. Lopalco	
		US- 2003-0092632	05-15-2003	T. Dragic	
		US- 2007-0026441 A1	02-01-2007	W.C. Olson et al.	
		US- 2004-0062767	04-01-2004	W.C. Olson et al.	
		US- 2003-0139571 A1	07-24-2003	T. Dragic et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
		WO 02/22077	03-21-2002			
		WO 03/072766	09-04-2003			
		WO 07/014114	02-01-2007			
		WO 97/47318 A	12-18-1997			
		WO 98/18826	05-07-1998			
		WO 02/064612	08-22-2002			

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet **3**of **47****Complete if Known**

Application Number	09/904,356
Filing Date	July 12, 2001
First Named Inventor	G.P. Allaway
Art Unit	1648
Examiner Name	Jeffery S. Parkin
Attorney Docket Number	43966-CB

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US- 10/081,128	02-22-2002	W.C. Olson et al.	
		US- 09/212,793	12-16-1998	W.C. Olson et al.	
		US- 08/663,616	06-14-1996	G.P. Allaway	
		US- 08/673,682	06-25-1998	G.P. Allaway	
		US- 08/874,570	06-13-1997	G.P. Allaway	
		US- 08/874,618	06-13-1997	G.P. Allaway	
		US- 09/118,415	07-17-1998	V.M. Litwinq	
		US- 60/358,886	02-22-2002	W.C. Olson et al.	
		US- 60/017,157	05-20-1996	D. Littman et al.	
		US- 60/266,738	02-06-2001	W.C. Olson et al.	
		US- 60/282,380	04-06-2001	W.C. Olson et al.	
		US- 60/019,715	06-14-1996	W.C. Olson et al.	
		US- 60/019,941	06-14-1996	G.P. Allaway et al.	
		US- 60/112,532	12-16-1998	W.C. Olson et al.	
		US- 60/185,667	02-29-2000	T. Dragic et al.	
		US- 60/205,839	05-19-2000	T. Dragic et al.	
		US- 60/267,231	02-07-2001	T. Dragic et al.	
		US- 60/272,203	02-18-2001	T. Dragic	
		US- 60/018,508	05-28-1996	C. Combadiere et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
		WO 01/55439	08-02-2001			
		WO 01/58915	08-16-2001			
		WO 01/58916	08-16-2001			
		WO 97/22698	06-26-1997			
		WO 97/44055	11-27-1997			
		WO 97/032019	09-04-1997			

Examiner Signature	Date Considered
--------------------	-----------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ² Applicant's unique citation designation number (optional). ³ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 5

of 47

Complete if Known

Application Number	09/904,356
Filing Date	July 12, 2001
First Named Inventor	G.P. Allaway
Art Unit	1648
Examiner Name	Jeffery S. Parkin
Attorney Docket Number	43966-CB

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ² *Number ⁴ *Kind Code ⁵ (if known)	MM-DD-YYYY			
		EP 114826 A2	10-24-2001			
		EP 1148127 A2	10-24-2001			
		EP 1149582 A2	10-31-2001			
		EP 1199360 A2	04-24-2002			
		EP 1482042 A1	12-01-2004			
		EP 0815137	12-12-1996			

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

(Use as many sheets as necessary)

Sheet	6
-------	---

of 47

Application Number	09/904,356
Filing Date	July 12, 2001
First Named Inventor	G.P. Allaway
Art Unit	1648
Examiner Name	Jeffery S. Parkin
Attorney Docket Number	43966-CB

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	09/904,356
Filing Date	July 12, 2001
First Named Inventor	G.P. Allaway
Art Unit	1648
Examiner Name	Jeffery S. Parkin
Attorney Docket Number	43966-CB

Sheet 7

of 47

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		PCT International Search Report issued June 9, 1997 for International Application Publication No. WO 97/26009	
		PCT International Search Report issued July 5, 1997 for International Application Publication No. WO 98/56421	
		PCT International Search Report issued September 3, 1997 for International Application Publication No. WO 97/47319	
		PCT International Search Report issued September 12, 1998 for International Application Publication No. WO 98/56421	
		PCT International Search Report issued September 3, 1997 for International Application Publication No. WO 97/47318	
		PCT International Search Report issued June 7, 2000 for International Application Publication No. WO 00/35409	
		PCT International Search Report issued August 13, 2003 for International Application Publication No. WO 03/072766	
		PCT International Search Report issued April 23, 2002 for International Application Publication No. WO 02/22077	
		PCT International Search Report issued July 31, 2003 for International Application Publication No. WO 02/083172	
		PCT International Preliminary Examination Report issued January 27, 2000 for International Application Publication No. WO 98/56421	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered; whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Application Number		09/904,356
	Filing Date		July 12, 2001
	First Named Inventor		G.P. Allaway
	Art Unit		1648
	Examiner Name		Jeffery S. Parkin
	Attorney Docket Number		43966-CB

Sheet

8

of

47

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		PCT International Preliminary Examination Report issued July 10, 1998 for International Application Publication No. WO 97/37005	
		PCT International Preliminary Examination Report issued October 16, 1999 for International Application Publication No. WO 97/47319	
		PCT International Preliminary Examination Report issued September 28, 2005 for International Application Publication No. WO 03/072766	
		PCT International Preliminary Examination Report issued April 5, 2006 for International Application Publication No. WO 03/072766	
		PCT International Preliminary Examination Report issued February 15, 2001 for International Application Publication No. WO 00/35409	
		PCT International Preliminary Examination Report issued December 24, 2003 for International Application Publication No. WO 02/083172	
		PCT Written Opinion issued May 25, 2005 in connection with International Application Publication No. WO 03/072766	
		European Supplementary Partial Search Report issued September 27, 2004 for European Application No. 99966466	
		European Supplementary Partial Search Report issued February 19, 2003 for European Patent Application No. 98931261.6	
		European Supplementary Partial Search Report issued August 26, 2004 for European Patent Application No. 97930120.7	

Examiner
Signature

Date

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	09/904,356		
		Filing Date	July 12, 2001		
		First Named Inventor	G.P. Allaway		
		Art Unit	1648		
		Examiner Name	Jeffery S. Parkin		
Sheet	9	of	47	Attorney Docket Number	43966-CB

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		European Supplementary Partial Search Report issued November 8, 2004 for European Patent Application No. 97930120.7	
		European Supplementary Search Report issued April 21, 2006 for European Application No. 03713632.2	
		European Supplementary Search Report issued March 6, 2002 for European Patent Application No. 97917856.3	
		European Supplementary Search Report issued April 27, 2006 for European Patent Application No. 01970984.9	
		April 21, 2006 Supplementary European search report under Article 157(2) (a) in connection with European Application No. 03 713 632.2	
		February 9, 2004 Office action in connection with U.S. Application Serial No. 10/116,797	
		European Patent Office Communication issued November 11, 2004 in connection with European Patent Application No. 97930120.7	
		Genbank Sequence Report, Accession Entry X91492 for H. sapiens Chem13, submitted September 14, 1995	
		Janeway and Travers (1994). Immunobiology, Current Biology Ltd., San Francisco. Pp. 10:27-10:42	
		Stryer (1988). Biochemistry, 3rd edition. Pp. 984-988	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	09/904,356
Filing Date	July 12, 2001
First Named Inventor	G.P. Allaway
Art Unit	1648
Examiner Name	Jeffery S. Parkin
Attorney Docket Number	43966-CB

Sheet 10 of 47

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		December 17, 2003 Third Party Observations in connection with European Application No. 97904948.3	
		February 27, 2004 Third Party Observations in connection with European Application No. 97904948.3	
		Abaza et al. (1992). Effects Of Amino Acid Substitutions Outside An Antigenic Site On Protein Binding To Monoclonal Antibodies Of Predetermi... J. Prot. Chem, 11(5):433- 443	
		Alkhatib, et al. (1996). Abstract At 3rd Conference On Retroviruses	
		Alkhatib, G., et al. (1996). CC CKR5: A RANTES, MIP-1a, MIP-1β Receptor As A Fusion Cofactor For Macrophage-Tropic HIV-1. Science, 272:1955-1958	
		Alkhatib, G., et al. (1997). HIV Co-Receptor Activity Of CCR5 And Its Inhibition By Chemokines: Independence From G Protein Signaling and Importance... Virology, 234:340-348	
		Allaway, G.P., et al. (1993). Synergistic Inhibition Of HIV-1 Envelope-Mediated Cell Fusion By CD4-Based Molecules In Combination... AIDS Res. Hum. Retroviruses, 9:581-587	
		Allaway, G.P., (1995). Expression And Characterization Of CD4-IgG2, A Novel Heterotetramer That Neutralizes Primary HIV Type 1... Aids Res. Hum. Retrovirus, 11:533-539	
		Amara, A., et al. (1997). HIV Coreceptor Downregulation As Antiviral Principle: SDF-La-Dependent Internalization Of The Chemokine Receptor... J. Exp. Med., 186:139-146	
		Arenzana-Selsdedos, F., et al. (1996). HIV Blocked By Chemokine Antagonist. Nature, 383:400	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/904,356
		Filing Date	July 12, 2001
		First Named Inventor	G.P. Allaway
		Art Unit	1648
		Examiner Name	Jeffery S. Parkin
Sheet 11	of 47	Attorney Docket Number	43966-CB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Arthos, J., et al. (1989). Identification Of The Residues In Human CD4 Critical For The Binding Of HIV. Cell, 57:469-481	
		Ashorn, P.A., et al. (1990). Human Immunodeficiency Virus Envelope Glycoprotein/CD4 Mediated Fusion Of Nonprimate Cells With Human Cells. J. Virol., 64:2149-2156	
		Attanasio, et al. (1991). Anti-Idiotypic Antibody Response To Monoclonal Anti-CD4 Preparations in Nonhuman Primate Species. J. Immunol., 146:507-514	
		Baba, et al. (1998). Mechanism Of Inhibitory Effect Of Dextran Sulfate And Heparin On Replication Of Human Immunodeficiency Virus In... Proc. Natl. Acad. Sci., 85:6132-6135	
		Back, D.J. (1999). Pharmacological Issues Relating To Viral Resistance. Infection, 27(Suppl.2):S42-S44	
		Balzarini, et al. (1995). Suppression Of The Breakthrough Of HIV-1 In Cell Culture By Thiocarboxanilide Derivatives... Proc. Natl. Acad. Sci., 92:5470-5474	
		Baulerle and Huttner (1987). Tyrosine Sulfation Is A Trans-Golgi-Specific Protein Modification. Cell. Biol., 105:2655-2663	
		Berger, et al. (1996). Abstract No. 002, 8 at Keystone Symposium	
		Berger E.A. (1997). HIV Entry And Tropism: The Chemokine Receptor Connection. AIDS, 11(Suppl.A):S3-S16	
		Berger, et al. (1999). Chemokine Receptors As HIV-1 Coreceptors: Roles In Viral Entry, Tropism And Disease. Ann. Rev. Immunol., 17:657-700	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/904,356
		Filing Date	July 12, 2001
		First Named Inventor	G.P. Allaway
		Art Unit	1648
		Examiner Name	Jeffery S. Parkin
Sheet 12 of 47	Attorney Docket Number	43966-CB	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Bleul, C.C., et al. (1991). The Lymphocyte Chemoattractant SDF-1 Is A Ligand For LESTR/Fusion And Blocks HIV-1 Entry. Nature, 382:829-832	
		Brelot, A., et al. (1997). Role Of The First And Third Extracellular Domains Of CXCR4 In Human Immunodeficiency Virus Coreceptor Activity. J. Virol., 71:4744-4751	
		Brenner, T.J., et al. (1996). Relation Between HIV-1 Syncytium Inhibition Antibodies And Clinical Outcome In Children. Lancet, 337:1001-1005	
		Broder, et al. (1993). The Block To HIV-1 Envelope Glycoprotein-Mediated Membrane Fusion In Animal Cells Expressing Human CD4... Virol., 193:483-491	
		Broder, et al. (1996). HIV And The 7-Transmembrane Domain Receptors. Pathobiology, 64(4):171-179	
		Burkly, L., et al. (1995). Synergistic Inhibition Of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein-Mediated Cell Fusion and Infection... J. Virol., 69:4267-4273	
		Burton, D.R., et al. (1994). Efficient Neutralization Of Primary Isolates Of HIV-1 By A Recombinant Human Monoclonal Antibody. Science, 266:1024-1027	
		Busso, et al. (1991). HIV-Induced Syncytium Formation Requires The Formation Of Conjugates Between Virus-Infected And Uninfected T-Cells In Vitro. AIDS, 5:1425-1432	
		Cammack, N. (1999). Human Immunodeficiency Virus Type 1 Entry And Chemokine Receptors: A New Therapeutic Target. Antiviral Chemistry And Chemotherapy, 10:53-62	
		Capon, D.J., et al. (1989). Designing CD4 Immuno adhesions For AIDS Therapy. Nature, 337:525-531	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Sheet 13 of 47	Application Number	09/904,356
	Filing Date	July 12, 2001
	First Named Inventor	G.P. Allaway
	Art Unit	1648
	Examiner Name	Jeffery S. Parkin
Attorney Docket Number		43966-CB

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Chan, D.C., et al. (1998). Evidence That A Prominent Cavity In The Coiled Coil Of HIV Type 1 Gp41 Is An Attractive Drug Target. Proc. Natl. Acad. Sci., 95:15613-15617	
		Chan, D.C., et al. (1998). HIV Entry And Its Inhibition. Cell, 93:681-684	
		Charo, et al. (1994). Molecular Cloning And Functional Expression Of Two Monocyte Chemoattractant Protein 1 Receptors Reveals... Proc. Natl. Acad. Sci., 91:2752-2756	
		Chen, et al. (1997). Genetically Divergent Strains Of Simian Immunodeficiency Virus Use CCR5 As A Coreceptor For Entry. J. Of Virol., 71(4):2705-2714	
		Choe, H., et al. (1996). The Beta-Chemokine Receptors CCR3 And CCR5 Facilitate Infection By Primary HIV-1 Isolates. Cell, 85:1135-1148	
		Clapham, P.R., et al. (1991). Specific Cell Surface Requirements For The Infection Of CD4-Positive Cells By Human Immunodeficiency Virus Types 1 And 2... Virol., 181:703-715	
		Co, et al. (1991). Humanized Antibodies For Antiviral Therapy. Proc. Natl. Acad. Sci., 88:2869-2873	
		Cocchi, F. (1995). Identification Of RANTES, MIP-1alpha And MIP-1beta As The Major HIV-Suppressive Factors Produced By CD8+ T-Cells. Science, 270:1811-1815	
		Combadiere, et al. (1995). Cloning And Functional Expression Of A Human... J. Biol. Chem., 270, 16491-16494 (NOTE - Erratum In: J. Biol. Chem.1995 Dec 15; 270(50):30235))	
		Combadiere, et al. (1996). Cloning And Functional Expression Of CC CKR5, A Human Monocyte CC Chemokine Receptor Selective For... J. Leukos. Biol., 60:147-152	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Sheet 14 of 47	Application Number	09/904,356
	Filing Date	July 12, 2001
	First Named Inventor	G.P. Allaway
	Art Unit	1648
	Examiner Name	Jeffery S. Parkin
	Attorney Docket Number	43966-CB

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Connor, R.I., et al., (1997). Change In Co-Receptor Use Correlates With Disease Progression In HIV-1 Infected Individuals. J. Exp. Med., 185:621-628	
		Cormier, E.G., et al. (2000). Specific Interaction Of CCR5 Amino-Terminal Domain Peptides Containing Sulfotyrosines With HIV-1 Envelope...Proc. Natl. Acad. Sci., 97:5762-5767	
		Crump, M.P., et al. (1997). Solution Structure And Basis For Functional Activity Of Stromal-Cell Derived Factor-1: Disassociation Of CXCR4 Activation... EMBO, 16:6996-7007	
		Cruse, et al. (1995). Illustrated Dictionary Of Immunology, CRC Press, Inc, Boca Raton, FL., 143:QR180.4.C78	
		Cushman, M., et al. (1991). Preparation And Anti-HIV Activities Of Aurintricarboxylic Acid Fractions And Analogues: Direct Correlation Of... J. Med. Chem., 34:329-337	
		Daar, E.S. (1990). High Concentrations Of Recombinant Soluble CD4 Are Required To Neutralize Primary Human Immunodeficiency Virus... Proc. Natl. Acad. Sci., 87:6574-6578	
		Dalglish, A.G., et al. (1984). The CD4 (T4) Antigen Is An Essential Component Of The Receptor For The AIDS Retrovirus. Nature, 312:763-766	
		Dalglish, A.G. (1995). HIV And CD26. Nature Medicine, 1:881-882	
		De Rossi, A., et al. (1995). Synthetic Peptides From The Principle Neutralizing Domain Of Human Immunodeficiency Virus Type 1 (HIV-1) Enhance HIV-1... Virology, 184:187-196	
		Dean, M., et al. (1996). Genetic Restriction Of HIV-1 Infection And Progression To AIDS By A Deletion Allele Of The CKR5 Structural Gene. Science, 273:1856-1862	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	09/904,356
Filing Date	July 12, 2001
First Named Inventor	G.P. Allaway
Art Unit	1648
Examiner Name	Jeffery S. Parkin
Attorney Docket Number	43966-CB

Sheet 15 of 47

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		De Clerq, et al. (1992). Potent And Selective Inhibition Of Human Immunodeficiency Virus (HIV)-1 and HIV-2 Replication By A Class Of... Proc. Natl. Acad. Sci., 89:5286-5290	
		De Clerq, et al. (1994). Highly Potent And Selective Inhibition Of Human Immunodeficiency Virus By The Bicyclam... Antimicrobial Agents and Chemotherapy, 38:668-674	
		De Clerq, et al. (1995). Antiviral Therapy For Human Immunodeficiency Virus Infections. J. Clin. Microbiol. Rev., 8(2):200-239	
		Deen, K.C., et al. (1988). A Soluble Form Of CD4(T4) Protein Inhibits AIDS Virus Infection. Nature, 331:82-84	
		Deng, H., et al. (1996). Identification Of A Major Co-Receptor For Primary Isolates Of HIV-1. Nature, 381:661-666	
		Deng, X., et al. (1999). A Synthetic Peptide Derived From Human Immunodeficiency Virus Type 1 Gp120 Down-Regulates The Expression And Function... Blood, 94(4):1165-1173	
		Dettin, et al. (2003). CCR5 N-Terminus Peptides Enhance X4 HIV-1 Infection By CXCR4 Up-Regulation. Biochem. Biophys. Res. Commun., 307(3):640-646	
		Dikic (1996). Regulation of HIV-1 Infection by Chemokine Receptors. Acta Med. Croatica, 50:163-168	
		Ditzel, et al. (1998). The CCR5 Receptor Acts As An Alloantigen In CCR5Δ32 Homozygous Individuals: Identification Of Chemokine And... Proc. Natl. Acad. Sci., 95(9):5241-5245	
		Donzella, G.A., et al. (1998). AMD3100, A Small Molecule Inhibitor Of HIV-1 Entry Via The CXCR4 Co-Receptor. Nat. Med., 4:72-77	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Application Number		09/904,356		
	Filing Date		July 12, 2001		
	First Named Inventor		G.P. Allaway		
	Art Unit		1648		
	Examiner Name		Jeffery S. Parkin		
Sheet	16	of	47	Attorney Docket Number	43966-CB

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Doranz, B.J., et al. (1996). A Dual-Tropic Primary HIV-1 Isolate That Uses Fusin And Beta-Chemokine Receptors CKR-5, CKR-3 And CKR-2b As Fusion Cofactors. Cell, 85:1149-1158	
		Doranz, B.J., et al. (1997). Two Distinct CCR5 Domains Can Mediate Co-Receptor Usage By Human Immunodeficiency Virus Type 1. J. Virol., 71:6305-6314	
		Doranz, B.J., et al. (1997). A Small Molecule Inhibitor Directed Against The Chemokine Receptor CXCR4 Prevents Its Use As An HIV-1 Co-Receptor. J. Ex. Med., 186:1395-1400	
		Dragic, T.V., et al. (1995). Proteinase-Resistant Factors In Human Erythrocyte Membranes Mediated CD-4 Dependent Fusion With Cells Expressing... J. Virol., 69:1013-1018	
		Dragic, T.V., et al. (1996). HIV-1 Entry Into CD4+Cells Is Mediated By The Chemokine Receptor CC-CKR-5. Nature, 381:667-673	
		Dragic, T.V., et al. (1998). Amino-Terminal Substitutions In The CCR5 Coreceptor Impair Gp120 Binding And Human Immunodeficiency Virus Type 1 Entry. J. Virol., 72(1):279-285	
		Dragic, et al. (2000). A Binding Pocket For A Small Molecule Inhibitor Of HIV-1 Entry Within The Transmembrane Helices Of CCR5. Proc. Natl. Acad. Sci., 97(10):5639-5644	
		Eckert, D.M., et al. (1999). Inhibiting HIV-1 Entry: Discovery Of D-Peptide Inhibitors That Target The gp41 Coiled-Coil Pocket. Cell, 99:103-115	
		Eugen-Olsen, J., et al. (1997). Heterozygosity For A Deletion In The CKR-5 Gene Leads To Prolonged AIDS-Free Survival And Slower CD4 T-Cell... AIDS, 11:305-310	
		Fahey, J.L., et al. (1992). Status Of Immune-Based Therapies In HIV Infection And AIDS. Clin. Exp. Immunol., 88:1-5	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	09/904,356
Filing Date	July 12, 2001
First Named Inventor	G.P. Allaway
Art Unit	1648
Examiner Name	Jeffery S. Parkin
Attorney Docket Number	43966-CB

Sheet 17 of 47

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Farzan, M., et al. (1998). A Tyrosine-Rich Region In The N-Terminus Of CCR5 Is Important For Human Immunodeficiency Virus Type 1 Entry And Mediates...J. Virol., 72:1160-1164	
		Farzan, M., et al. (1999). Tyrosine Sulfation Of The Amino-Terminus Of CCR5 Facilitates HIV-1 Entry. Cell, 96:667-676	
		Farzan, M., et al. (2000). A tyrosine-sulfated peptide based on the N terminus of CCR5 interacts with a CD4-enhanced epitope of the HIV-1... J. Biol. Chem., 275:33416-33521	
		Feng, et al. (1996). Abstract No. 116,21 at Keystone Symposium	
		Feng, Y., et al. (1996). HIV-1 Entry Cofactor: Functional cDNA Cloning Of A Seven-Transmembrane, g Protein-Coupled Receptor. Science, 272:872-877	
		Ferrer, M., et al. (1999). Selection Of gp-41 Mediated HIV-1 Cell Entry Inhibitors From Biased Combinatorial Libraries Of Non-Natural... Nature. Struct. Biol., 6:953-959	
		Flexner, C. and Hendrix, C. (1997). "Pharmacology Of Antiretroviral Agents", in AIDS: Bio,... 4th Edition, De Vita V., et al. eds., Lippincott-Raven Publishers. Pp. 479-493	
		Fouts, T.R., et al. (1997). Neutralization Of The Human Immunodeficiency Virus Type 1 Primary Isolate JR-FL By Human Monoclonal Antibodies... J. Virol., 71:2779-2785	
		Fox, J.L. (1994). No Winners Against Aids. Bio/Technology, 12:128	
		Fradd, F. and Mary, M.E. (1989). AIDS Vaccines: An Investor's Guide, Shearman Lehman Hutton. P. 10:(Fig. 2)	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number 09/904,356

Filing Date July 12, 2001

First Named Inventor G.P. Allaway

Art Unit 1648

Examiner Name Jeffery S. Parkin

Sheet 18 of 47

Attorney Docket Number 43966-CB

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Furuta, R.A., et al. (1998). Capture Of An Early Fusion-Active Conformation Of HIV-1 gp41. Nature Struct. Biol., 5(4):276-279	
		Gait, M.J and Karn, J. (1995). Progress In anti-HIV Structure Based Drug Design. TIBTECH, 13:430-438	
		Gauduin, M.C., et al. (1996). Effective Ex Vivo Neutralization Of Plasma HIV-1 By Recombinant Immunoglobulin Molecules. J. Virol., 70:2586-2592	
		Gauduin, M.C., et al. (1997). Passive Immunization With A Human Monoclonal Antibody Protects hu-PBL-SCID Mice Against Challenge By Primary... Nature Medicine, 3:1389-1393	
		Ghorpade A., et al. (1998). Role Of The Beta-Chemokine Receptors CCR3 And CCR5 In Human Immunodeficiency Virus Type 1 Infection Of Monocytes And.... J. Virol, 72:3351-3361	
		Golding, H., et al. (1992). LFA-1 Adhesion Molecules Are Not Involved In The Arly Stages Of HIV-1 Env-Mediated Cell Membrane Fusion. AIDS Res. Hum. Retroviruses, 8:1593-1598	
		Gong, J.H., et al. (1995). Antagonists Of Monocyte Chemoattractant Protein 1 Identified By Modification Of Functionally Critical NH2-Terminal.... J. Exp. Med., 181:631-640	
		Gong, J.H., et al. (1996). RANTES And MCP-3 Antagonists Bind Multiple Chemokine Receptors. J. Biol. Chem., 371:10521-10527	
		Greene, et al. (2001). Anti-CCR5 Antibodies In Sera Of HIV-Positive Individuals. Human Immunol., 62(2):143-145	
		Harrington, R.D. and Geballe, A.P. (1993). Cofactor Requirement For Human Immunodeficiency Virus Type 1 Entry Into A CD4-Expressing Human Cell Line. J. Virol., 67:5939-5947	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	09/904,356
Filing Date	July 12, 2001
First Named Inventor	G.P. Allaway
Art Unit	1648
Examiner Name	Jeffery S. Parkin
Attorney Docket Number	43966-CB

Sheet 19 of 47

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Hattori, T., et al. (1989). Involvement Of Trypsin-Related Cellular Protease(S) In Human Immunodeficiency Virus Type 1 Infection. FEBS Letters, 248:48-52	
		Haynes, B.F. (1996). Updates On The Issues Of HIV Vaccine Development. Ann. Med., 28:39-41	
		He, Jianglin, et al. (1997). CCR3 And CCR5 Are Co-Receptors For HIV-1 Infection Of Microglia. Nature, 385:645-649	
		Heath, et al. (1997). Chemokine Receptor Usage By Human Eosinophils. The Importance Of CCR3 Demonstrated Using An Antagonistic Monoclonal... J. Clin. Invest., 99:178-184	
		Heidenreich, et al. (1995). Application Of Antisense Technology To Therapeutics. Mol. Med. Today, 1:128-133	
		Hildreth, et al. (1989). Involvement Of A Leukocyte Adhesion Receptor (LFA-1) In HIV-Induced Syncytium Formation. Science, 244:1075-1078	
		Hill, C.M., et al. (1998). The Amino Terminus Of Human CCR5 Is Required For Its Function As A Receptor To Diverse Human And Simian Immunodeficiency... Virology, 248:357-371	
		Hirata, Y. (1989). Characterization Of IL-6 Receptor Expression By Monoclonal And Polyclonal Antibodies. J. Immun., 2900-2906	
		Howard, O.M.Z., et al. (1998). Small Molecule Inhibitor Of HIV-1 Cell Fusion Blocks Chemokine Receptor-Mediated Fusion. J. Leuk. Biol., 64:6-13	
		Hwang, S.S., et al. (1991). Identification Of The Envelope V3 Loop As The Primary Determinant Of Cell Tropism In HIV-1. Science, 253:71-74	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	09/904,356
Filing Date	July 12, 2001
First Named Inventor	G.P. Allaway
Art Unit	1648
Examiner Name	Jeffery S. Parkin
Attorney Docket Number	43966-CB

Sheet 20 of 47

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Jacobson, J.M., et al. (1993). Passive Immunotherapy In The Treatment Of Advanced Human Immunodeficiency Virus Infection. J. Infect. Dis., 168:298-305	
		Jacobson, J., et al. (1999). Results Of A Phase..., A Novel Inhibitor Of HIV Entry. Abstracts Of The 39th Interscience Conference On Antimicrobial Agents And Chemotherapy 14	
		Ji, H., et al. (1999). Inhibition Of Human Immunodeficiency Virus Type 1 Infectivity By The gp41 Core: Role Of A Conserved Hydrophobic Cavity In... J. Virol., 73:8578-8586	
		Jiang, S., et al. (1993). HIV-1 Inhibition By A Peptide. Nature, 365:113	
		Jones, S.A., et al. (1997). Chemokine Antagonists That Discriminate Between Interleukin-8 Receptors. J. Biol. Chem., 272:16166-16199	
		Karwowska, S., et al. (1991). Passive Immunization For The Treatment And Prevention Of HIV Infection. Biotech. Therap., 2:31-48	
		Katinger, H. (1994). Human Monoclonal Antibodies For Passive Immunotherapy Of HIV-1. Antibiot. Chemother., 46:23-37	
		Kilby, J.M., et al. (1998). Potent Suppression Of HIV-1 Replication In Humans By T-20, A Peptide Inhibitor Of gp41-Mediated Virus Entry. Nature Med., 4:1302-1307	
		Klotman, et al. (1995). Transgenic Models Of HIV-1. AIDS, 9(4):313-324	
		Konigs, C., et al. (2000). Monoclonal Antibody Screening Of Phage-Displayed Random Peptide Library Reveals Mimotopes Of Chemokine... Eur. J. Immunol., 30(4):1162-1171	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	09/904,356
Filing Date	July 12, 2001
First Named Inventor	G.P. Allaway
Art Unit	1648
Examiner Name	Jeffery S. Parkin
Attorney Docket Number	43966-CB

Sheet 21 of 47

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Konishi, K., et al. (2000). Synthesis Of Peptides Mimicking Chemokine Receptor CCR5 And Their Inhibitory Effects Against HIV-1... Chem. Pharm. Bull., Tokyo, 48(2):308-309	
		Koup, R.A., et al. (1996). Defining Antibody Protection Against HIV-1 Transmission In Hu-PBL-SCID Mice. Immunology, 8:263-268	
		Kwong, P.D. et al. (1998). Structure Of An HIV gp120 Envelope Glycoprotein In Complex With The CD4 Receptor And Neutralizing Human Antibody. Nature, 393:648-659	
		Laal, S., et al. (1994). Synergistic Neutralization Of Human Immunodeficiency Virus Type 1 By Combinations Of Human Monoclonal Antibodies. J. Virol., 68:4001-4008	
		LaCasse, R.A., et al. (1999). Fusion-Competent Vaccines: Broad Neutralization Of Primary Isolates Of HIV. Science, 283:357-362	
		Lee, B., et al. (1999). Epitope Mapping Of CCR5 Reveals Multiple Conformational States And Distinct But Overlapping Structures Involved In... J. Biol. Chem., 9617-9626	
		Lehner, et al. (2001). Immunogenicity Of The Extracellular Domains Of C-C Chemokine Receptor 5 And The In Vitro Effects On Simian... Journal Of Immunology, 166(12):7446-7455	
		Levy, J.A. (1996). Controlling HIV Pathogenesis: The Role Of The Non-Cytotoxic Anti-HIV Response Of CD8+ Cells. Immunology Today, 17:217-224	
		Li, A., et al. (1997). Synergistic Neutralization Of Chimeric SIV/HIV Type 1 Virus With Combinations Of Human Anti-HIV Type 1... AIDS Res. Hum. Retroviruses, 12:647-56	
		Li, A.H., et al. (1998). Synergistic Neutralization Of Simian-Human Immunodeficiency Virus SHIV-vpu+ By Triple And Quadruple Combination Of Human... J. Virol., 72:3235-3240	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Sheet	22	of	47	Application Number	09/904,356
				Filing Date	July 12, 2001
				First Named Inventor	G.P. Allaway
				Art Unit	1648
				Examiner Name	Jeffery S. Parkin
				Attorney Docket Number	43966-CB

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Litwin, V.M., et al. (1996). Human Immunodeficiency Virus Type 1 Membrane Fusion Mediated By A Laboratory-Adapted Strain And A Primary Isolate..., J. Virol., 70(9):6437-6441	
		Loetscher, M., et al. (1994). Cloning Of A Human Seven-Transmembrane Domain Receptor, LESTR, That Is Highly Expressed In Leukocytes. J. Biol. Chem., 269:232-237	
		Mack, M., et al. (1998). Aminooxypentane-RANTES Induces CCR5 Internalization But Inhibits Recycling: A Novel Inhibitory Mechanisms Of HIV... J. Ex. Med., 187:1215-1224	
		Mackay, C.R. (1996). Chemokine Receptors And T Cell Chemotaxis. J. Exp. Med., 84:799-802	
		Maddon, P.J., et al. (1986). The T4 Gene Encodes The AIDS Virus Receptor And Is Expressed In The Immune System And The Brain. Cell, 47:333-348	
		Markosyan, R.M., et al. (2002). The Mechanism Of Inhibition Of HIV-1 Entry Env-Mediated Cell-Cell Fusion By Recombinant Cores Of gp41 Ectodomain. Virology, 302:174-184	
		McKnight, A.D., et al. (1997). Inhibition Of Human Immunodeficiency Virus Fusion By A Monoclonal Antibody To A Coreceptor (CXCR4) Is Both Cell Type... J. Virol., 71:1692-1696	
		Mellors, J.W. (1996). Closing In On Human Immunodeficiency Virus-1. Nature Medicine, 2(3):274-275	
		Mohan, P., et al. (1992). Sulfonic Acid Polymers As A New Class Of Human Immunodeficiency Virus Inhibitors. Antiviral Res., 18:139-150	
		Moser, B., et al. (1993). Interleukin-8 Antagonists Generated By N-Terminal Modification. J. Biol. Chem., 268:7125-7128	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	09/904,356
Filing Date	July 12, 2001
First Named Inventor	G.P. Allaway
Art Unit	1648
Examiner Name	Jeffery S. Parkin
Attorney Docket Number	43966-CB

Sheet 23 of 47

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Mosier, D.E. (1990). Immunodeficient Mice Xenografted With Human Lymphoid Cells: New Models For In-Vivo Studies Of Human Immunobiology And... J. Clin. Immuno., 10(4):185-191	
		Nagasawa, et al. (1994). Molecular Cloning And Structure Of A Pre-B-Cell Growth-Stimulating Factor. Proc. Natl. Acad. Sci., 91:2305-2309	
		Nagashima, K.A., et al. (2001). Human Immunodeficiency Virus Type 1 Entry Inhibitors PRO 542 And T-20 Are Potently Synergistic In Blocking... J. Infect. Dis., 183:1121-1125	
		Nakano, T., et al. (1995). Vascular smooth muscle cell-derived, Gla-containing growth-potentiating factor for Ca2+ mobilizing growth.... J. Biol. Chem., 270(11):5702-5705	
		Neote, et al. (1993). Molecular cloning, functional expression, and signaling characteristics of a C-C chemokine receptor. Cell, 72:415-425	
		Oberg, B and Vrang, L. (1990). Screening for new agents. Eur. J. Clin. Microbiol. Infect. Dis., 9(7):466-471	
		Oberlin, E., et al. (1996). The CXC Chemokine SDF-1 is the Ligand for LESTR/fusion and prevents infection by T-cell-line-adapted HIV-1. Nature, 382: 833-835	
		Oellerich, M., (1984). Enzyme-Immunoassay: A Review. J. Clin. Chem. Clin. Biochem., 22(12):895-904	
		Olson, et al., (1999). Differential Inhibition of Human Immunodeficiency Virus Type 1 Fusion, gp120 Binding and CC-chemokine Activity of Monoclonal... J. Virol., 73:4145-4155	
		Opperman, (2004). Chemokine Receptor CCR5: Insights Into Structure, Function, And Regulation. Cell. Signal., 16:1201-1210	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number 09/904,356

Filing Date July 12, 2001

First Named Inventor G.P. Allaway

Art Unit 1648

Examiner Name Jeffery S. Parkin

Attorney Docket Number 43966-CB

Sheet

24

of

47

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Parren, et al. (2001). Antibody Protects Macaques Against Vaginal Challenge With A Pathogenic R5 Simian/Human Immunodeficiency Virus At Serum.... J. Virol., 75:8340-8347	
		Partidos, C., et al. (1992). The Effect Of Orientation Of Epitopes On The Immunogenicity Of Chimeric Synthetic Peptides Representing... Molecular Immunology, 29(5):651-658	
		Poignard, P., et al. (1999). Neutralizing Antibodies Have Limited Effects On The Control Of Established HIV-1 Infection In-Vivo. Immunity, 10:431-438	
		Posner, M.R., et al. (1993). Neutralization Of HIV-1 By F105, A Human Monoclonal Antibody To The CD4 Binding Site Of gp120. J. Acq. Immune Defic. Synd., 6:7-14	
		Power, et al. (1995). Molecular Cloning And Functional Expression Of A Novel CC Chemokine Receptor Cdna From A Human Basophilic Cell Line. J. Biol. Chem., 270:1811-1815	
		Proudfoot, et al. (1996). Extension Of Recombinant Human RANTES By The Retention Of The Initiating Methionine Produces A Potent Antagonist. J. Biol. Chem., 271:2599-2603	
		Proudfoot, et al. (1999). Chemokine Receptors: Future Therapeutic Targets For HIV. Biochem. Pharmacol., 57:451-463	
		Proudfoot, et al. (2000). The Strategy Of Blocking The Chemokine System To Combat Disease. Immunol. Rev., 177:246-256	
		Queen, et al. (1989). A Humanized Antibody That Binds To The Interleukin 2 Receptor. Proc. Natl. Acad. Sci, 86:10029-10033	
		Rabut, G.E., et al. (1991). Alanine Substitutions Of Polar And Nonpolar Residues In The Amino-Terminal Domain Of CCR5 Differently Impair Entry Of.... J. Virol., 72:3464-3468	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/904,356
		Filing Date	July 12, 2001
		First Named Inventor	G.P. Allaway
		Art Unit	1648
		Examiner Name	Jeffery S. Parkin
Sheet 25	of 47	Attorney Docket Number	43966-CB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Raport, C.J., et al. (1996). Molecular Cloning And Functional Characterization Of A Novel Human CC-Chemokine Receptor (CCR5) For RANTES,... J. Biol. Chem., 271:1761-1766	
		Raport, C.J., et al. (1996). New Members Of The Chemokine Receptor Gene Family. Journal of Leukocyte Biology, 59:18-23	
		Raport, C.J., et al. (1996). AAC50598 submitted to NCBI on April 12, 1996 (CC Chemokine Receptor 5 sequence)	
		Richman, D.D. (1996). Antiretroviral Drug-Resistance: Mechanisms, Pathogenesis, Clinical Significance. Antivir. Chemother., 4:383-395	
		Rodriguez, G., et al. (1995). Mediation Of Human Immunodeficiency Virus Type 1 Binding By Interaction Of Cel Surface Heparin Sulfate Proteoglycans... J. Virol., 69:2233-2239	
		Rucker, et al. (1996). Regions In Beta-Chemokine Receptors CCR5 And CCR2b That Determine HIV-1 Cofactor Specificity. Cell, 87:437-446	
		Ruffing, et al. (1998). CCR5 Has An Expanded Ligand-Binding Repertoire And Is The Primary Receptor Used By MCP-2 On Activated T-Cells. Cell. Immunol., 160:160-168	
		Rudikoff, et al. (1982). Single Amino Acid Substitution Altering Antigen-Binding Specificity. Proc. Natl. Acad. Sci., 79:1979-1983	
		Samson, M., et al. (1996). Molecular Cloning And Functional Expression Of A New Human CC-Chemokine Receptor Gene. Biochem., 35:3362-3367	
		Sandberg, J. (1995). Developmental Pharmacology And Toxicology Of Anti-HIV Therapeutic Agents: Dideoxynucleosides. FASEB J., 9:1157-1163	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/904,356
		Filing Date	July 12, 2001
		First Named Inventor	G.P. Allaway
		Art Unit	1648
		Examiner Name	Jeffery S. Parkin
Sheet 26	of 47	Attorney Docket Number	43966-CB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Sato, et al. (1992). Anti-Cd7 Reagents Inhibit HIV-1 Induced Syncytium Formation. International Conference on AIDS, 8I. PA5 PoA 2017	
		Sato, et al. (1994). Identification Of CD7 Glycoprotein As An Accessory Molecule In HIV-1 Mediated Syncytium Formation And Cell Free Infection. J. Immunol., 152:5142-5152	
		Sato, et al. (1995). A Simple And Rapid Method For Preliminary Evaluation Of In Vivo Efficacy Of Anti-HIV Compounds In Mice. Antivir. Res., 27:151-163	
		Scarlatti, et al. (1997). In Vivo Evolution Of HIV-1 Co-Receptor Usage And Sensitivity To Chemokine-Mediated Suppression. Nature Medicine, 3(11):1259-1265	
		Schanberg, et al. (1995). Characterization Of Human CD7 Transgenic Mice. J. of Immunol., 155:2407-2418	
		Schols, D., et al. (1990). Dextran sulfate and other oyanionic anti-HIV compounds specifically interact with the viral gp120 Glycoprotein Expressed... Virology, 175:556-561	
		Schols, D., et al. (1991). Selective Inhibitory Activity Of Polyhydroxycarboxylates Derived From Phenolic Compounds Against Human... J. Acq. Immune Defic. Synd., 4:677-685	
		Schols, D., et al. (1999). CD26-Processed RANTES(3-68), But Not Intact RANTES, Has Potent Anti-HIV-1 Activity. Antiviral Res., 30:175-187	
		Simmons, G., et al. (1997). Potent Inhibition Of HIV-1 Infectivity In Macropages And Lymphocytes By A Novel CCR5 Antagonist. Science, 276:276-279	
		Sommerfelt, M.A., et al. (1995). Intercellular Adhesion Molecule 3, A Candidate Human Immunodeficiency Virus Type 1 Co-Receptor On Lymphoid... J. Gen. Virol., 76:1345-1352	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	09/904,356
Filing Date	July 12, 2001
First Named Inventor	G.P. Allaway
Art Unit	1648
Examiner Name	Jeffery S. Parkin
Attorney Docket Number	43966-CB

Sheet 27 of 47

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Steinberger, P., et al. (2000). Generation And Characterization Of A Recombinant Human CCR5-Specific Antibody. J. Biol. Chem., 275:36073-36078	
		Stewart, G.J. (1997). Increased Frequency Of CCR-5Δ32 Heterozygotes Among Long-Term Non-Progressors With HIV-1 Infection. AIDS, 11:1833-1838	
		Strizki, J.M., et al. (1997). A Monoclonal Antibody (12G5) Directed Against CXCR4 Inhibits Infection With The Dual-Tropic Human Immunodeficiency... J. Virol., 71:5678-5683	
		Su, et al. (1996). Preparation Of Specific Polyclonal Antibodies To A C-C Chemokine Receptor, CCR1, And Determination Of CCR1 Expression On... J. Leukos. Biol., 60:658-666	
		Thali, M., et al. (1992). Cooperativity Of Neutralizing Antibodies Directed Against The VS And CD4 Binding Regions Of The Human... J. Acq. Immune. Defic. Synd., 5:591-599	
		Tilley, S.A., et al. (1991). Potent Neutralization Of HIV-1 By Human And Chimpanzee Monoclonal Antibodies Directed Against Three... Sixieme Colloque Des Cent Gardes., 211-216	
		Tremblay, et al. (2000). Strong In Vitro Synergy Observed Between The Fusion... February 7th, 2000 Conference on Retroviruses and Opportunistic Infections, abstract 500	
		Tremblay, et al. (1999). Strong In Vitro Synergy Between The Fusion Inhibitor T-20 And The CXCR4 Blocker... Journal of Acquired Immune Deficiency Syndromes, 25(2):99-102	
		Trkola, A., et al. (2001). Potent, Broad-Spectrum Inhibition Of Human Immunodeficiency Virus Type 1 By The CCR5 Monoclonal Antibody PRO 140. J. Virol., 75:579-588	
		Trkola, A., et al. (1999). Cross-Clade Neutralization Of Primary Isolates Of Human Immunodeficiency Virus Type 1 By Human Monoclonal Antibodies... J. Virol., 73(5):4145-4155	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	09/904,356		
		Filing Date	July 12, 2001		
		First Named Inventor	G.P. Allaway		
		Art Unit	1648		
		Examiner Name	Jeffery S. Parkin		
Sheet	28	of	47	Attorney Docket Number	43966-CB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Trkola, A., et al. (1996). CD-4 Dependent, Antibody Sensitive Interactions Between HIV-1 And Its Co-Receptor CCR-5. Nature, 384:184-187	
		Trkola, A., et al. (1998). Neutralization Sensitivity Of Human Immunodeficiency Virus Type 1 Primary Isolates To Antibodies And CD40 based Reagents... J. Virol., 72:1876-1885	
		Tulip, W.R., et al. (1992). Crystal Structures Of Two Mutant Neraminidase-Antibody Complexes With Amino Acid Substitutions In The Interface. J. Mol. Biol., 227:149-159	
		Valentin, et al. (1990). The Leukocyte Adhesion Glycoprotein CD18 Participates In HIV Induced Syncytia Formation In Monocytoid And T Cells. J. of Immunology, 144:934-937	
		Valenzuela, A., et al. (1997). Neutralizing Antibodies Against The V3 Loop Of Human Immunodeficiency Virus Type 1 Block The CD4-Dependent And... J. Virol., 71(11):8289-8298	
		Vijh-Warrier, S., Pinter, A., Honnen, W.J., and Tilley, S.A. (1996). Synergistic Neutralization Of Human Immunodeficiency Virus Type 1 By A... J. Virol., 70:4466-4473	
		Vila-Coro, et al. (2000). HIV-1 Infection Through The CCR5 Receptor Is Blocked By Receptor Dimerization. Proc. Natl. Acad. Sci., 97(7):3388-3393	
		Vita, C., et al. (1999). Rational Engineering Of A Mini-Protein That Reproduces The Core Of The CD4 Site Interacting With HIV-1... Proc. Natl. Acad. Sci. 96:13091-13096	
		Wang, et al. (1994). Deletion Of T Lymphocytes In Human CD4 Transgenic Mice Induced By HIV-gp120 and gp120-Specific Antibodies From AIDS... Eur. J. Immunol., 24:1553-1557	
		Wells, T.N.C., et al. (1996). Selectivity And Antagonism Of Chemokine Receptors. Journal of Leukocyte Biology, 59:53-60	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/904,356
		Filing Date	July 12, 2001
		First Named Inventor	G.P. Allaway
		Art Unit	1648
		Examiner Name	Jeffery S. Parkin
Sheet 29	of 47	Attorney Docket Number	43966-CB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Wild, C., et al. (1992). A Synthetic Peptide Inhibitor Of Human Immunodeficiency Virus Replication: Correlation Between Solution... Proc. Natl. Acad. Sci., 89:10537-10541	
		Wild, C., et al. (1993). A synthetic peptide from HIV-1 Gp41 Is A Potent Inhibitor Of Virus Mediated Cell-Cell Fusion. AIDS Res. Humn. Retroviruses, 9:1051-1053	
		Wild, C., et al. (1994). Peptides Corresponding To A Predictive Alpha-Helical Domain Of Human Immunodeficiency Virus Type 1 gp41 Are... Proc. Natl. Acad. Sci., 91:9770-9774	
		Wild, C., et al. (1995). The Inhibitory Activity Of An HIV Type 1 Peptide Correlates With Its Ability To Interact With A Leucine... AIDS Res. Hum. Retroviruses, 11:323-325	
		Wu, et al. (1997). CCR5 Levels And Expression Pattern Correlate With Infectability By Macrophagetropic HIV-1 In Vitro. J. Exp. Med., 185(9):1681-1691	
		Wu, et al. (1997). Interaction Of Chemokine Receptor CCR5 With Its Ligands: Multiple Domains For HIV-1 gp120 Binding And A Single Domain... J. Exper. Med., 186(8):1373-1381	
		Wu, L., et al. (1996). CD4-Induced Interaction Of Primary HIV-1 gp120 Glycoproteins With The Chemokine Receptor CCR-5. Nature, 384:179-183	
		Yamagami, et al. (1994). cDNA Cloning And Functional Expression Of Human Monocyte Chemoattractant Protein 1 Receptor. Biochem. Biophys. Res. Commun., 212:1156-1162	
		Yarchoan, R. and Broder, S. (1992). Correlations Between The In Vitro And The In Vivo Activity Of Anti-HIV Agents: Implications For Future... J. Enzyme Inhibit., 6:99-11	
		Ylisastigui, L., et al. (1998). Synthetic Full Length And Truncated RANTES Inhibit HIV-1 Infection Or Primary Macrophages. AIDS, 12:977-984	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	09/904,356		
		Filing Date	July 12, 2001		
		First Named Inventor	G.P. Allaway		
		Art Unit	1648		
		Examiner Name	Jeffery S. Parkin		
Sheet	30	of	47	Attorney Docket Number	43966-CB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Zhang, Y.J., et al. (1994). Structure / Activity Analysis Of Human Monocyte Chemoattractant Protein-1 (MCP-1) By Mutagenesis. J. Biol. Chem., 269:15918-15924	
		July 16, 1998 Notice of Acceptance in connection with Australian Application No. 14387/95	
		November 27, 1996 Examiner's First Report in connection with Australian Application No. 14387/95	
		July 5, 2000 Notice of Acceptance in connection with Australian Application No. 62690/96	
		November 10, 1998 Examiner's First Report in connection with Australian Application No. 62690/96	
		September 14, 2006 Official Action in connection with Canadian Application No. 2,224,003	
		September 11, 2006 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 96 921 473.3	
		March 8, 2006 Summons to Oral Proceedings Pursuant to Rule 71(1) EPC in connection with European Application No. 96 921 473.3	
		February 24, 2005 Provision of a Copy of the Minutes in accordance with Rule 76(4) EPC in connection with European Application No. 96 921 473.3	
		February 24, 2005 Decision to Refuse a European Patent Application in connection with European Application No. 96 921 473.3	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/904,356
		Filing Date	July 12, 2001
		First Named Inventor	G.P. Allaway
		Art Unit	1648
		Examiner Name	Jeffery S. Parkin
Sheet 31	of 47	Attorney Docket Number	43966-CB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		August 30, 2004 Summons to Oral Proceedings Pursuant to Rule 71(1) EPC in connection with European Application No. 96 921 473.3	
		December 19, 2002 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 96 921 473.3	
		July 6, 2001 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 96 921 473.3	
		December 20, 1999 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 08/973,601	
		August 3, 1999 Advisory Action in connection with U.S. Application Serial No. 08/973,601	
		March 25, 1999 Office Action in connection with U.S. Application Serial No. 08/973,601	
		June 24, 1998 Office Action in connection with U.S. Application Serial No. 08/973,601	
		January 11, 2005 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/412,284	
		December 2, 2003 Final Office Action in connection with U.S. Application Serial No. 09/412,284	
		February 3, 2003 Office Action in connection with U.S. Application Serial No. 09/412,284	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	09/904,356
Filing Date	July 12, 2001
First Named Inventor	G.P. Allaway
Art Unit	1648
Examiner Name	Jeffery S. Parkin
Attorney Docket Number	43966-CB

Sheet 32 of 47

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		April 8, 2002 Advisory Action in connection with U.S. Application Serial No. 09/412,284	
		September 11, 2001 Final Office Action in connection with U.S. Application Serial No. 09/412,284	
		December 19, 2000 Office Action in connection with U.S. Application Serial No. 09/412,284	
		April 18, 2007 Office Action in connection with U.S. Application Serial No. 11/258,963	
		December 26, 2006 Office Action in connection with U.S. Application Serial No. 11/258,963	
		February 8, 2007 Office Action in connection with U.S. Application Serial No. 09/904,356	
		May 2, 2006 Final Office Action in connection with U.S. Application Serial No. 09/904,356	
		October 12, 2005 Office Action in connection with U.S. Application Serial No. 09/904,356	
		July 29, 2005 Advisory Action in connection with U.S. Application Serial No. 09/904,356	
		November 17, 2004 Final Office Action in connection with U.S. Application Serial No. 09/904,356	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/904,356
		Filing Date	July 12, 2001
		First Named Inventor	G.P. Allaway
		Art Unit	1648
		Examiner Name	Jeffery S. Parkin
Sheet 33	of 47	Attorney Docket Number	43966-CB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		July 1, 2003 Office Action in connection with U.S. Application Serial No. 09/904,356	
		September 29, 2003 Advisory Action in connection with U.S. Application Serial No. 09/118,415	
		January 28, 2003 Final Office Action in connection with U.S. Application Serial No. 09/118,415	
		April 9, 2002 Office Action in connection with U.S. Application Serial No. 09/118,415	
		August 14, 2001 Advisory Action in connection with U.S. Application Serial No. 09/118,415	
		November 24, 2000 Final Office Action in connection with U.S. Application Serial No. 09/118,415	
		February 11, 2000 Office Action in connection with U.S. Application Serial No. 09/118,415	
		August 3, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/891,062	
		July 17, 2006 Notice of Allowability in connection with U.S. Application Serial No. 09/891,062	
		May 18, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/891,062	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	09/904,356		
		Filing Date	July 12, 2001		
		First Named Inventor	G.P. Allaway		
		Art Unit	1648		
		Examiner Name	Jeffery S. Parkin		
Sheet	34	of	47	Attorney Docket Number	43966-CB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		August 8, 2005 Office Action in connection with U.S. Application Serial No. 09/891,062	
		March 21, 2005 Office Action in connection with U.S. Application Serial No. 09/891,062	
		May 28, 2004 Advisory Action in connection with U.S. Application Serial No. 09/891,062	
		September 24, 2003 Final Office Action in connection with U.S. Application Serial No. 09/891,062	
		December 18, 2002 Office Action in connection with U.S. Application Serial No. 09/891,062	
		April 30, 2007 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 11/544,346	
		March 3, 1997 Office Action in connection with U.S. Application Serial No. 08/627,684	
		June 23, 1997 Office Action in connection with U.S. Application Serial No. 08/663,616	
		March 13, 1997 Office Action in connection with U.S. Application Serial No. 08/673,682	
		November 28, 2000 Notice of Acceptance in connection with Australian Application No. 26074/97	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	09/904,356		
		Filing Date	July 12, 2001		
		First Named Inventor	G.P. Allaway		
		Art Unit	1648		
		Examiner Name	Jeffery S. Parkin		
Sheet	35	of	47	Attorney Docket Number	43966-CB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		July 13, 1999 Examiner's First Report in connection with Australian Application No. 26074/97	
		October 23, 2006 Official Action in connection with Canadian Application No. 2,250,829	
		May 27, 2005 Official Action in connection with Canadian Application No. 2,250,829	
		May 4, 2007 Summons to Attend Oral Proceedings Pursuant to Rule 71(1) EPC in connection with European Application No. 97917856.3	
		January 27, 2006 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3	
		October 21, 2005 Communication Pursuant to Article 115(2) EPC in connection with European Application No. 97917856.3	
		April 1, 2005 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3	
		August 5, 2004 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3	
		January 27, 2004 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3	
		May 9, 2003 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	09/904,356		
		Filing Date	July 12, 2001		
		First Named Inventor	G.P. Allaway		
		Art Unit	1648		
		Examiner Name	Jeffery S. Parkin		
Sheet	36	of	47	Attorney Docket Number	43966-CB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		March 6, 2002 Search Report Communication in connection with European Application No. 97917856.3	
		February 27, 2007 Notification of Reasons for Rejection in connection with Japanese Application No. 535610/97	
		May 19, 2006 Examiner's First Report in connection with Australian Application No. 2004233505	
		July 26, 2004 Notice of Acceptance in connection with Australian Application No. 35106/01	
		July 5, 2004 Examiner's Second Report in connection with Australian Application No. 35106/01	
		November 1, 2002 Examiner's First Report in connection with Australian Application No. 35106/01	
		December 4, 2001 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 08/831,823	
		January 16, 2001 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 08/831,823	
		September 26, 2000 Advisory Action in connection with U.S. Application Serial No. 08/831,823	
		April 11, 2000 Final Office Action in connection with U.S. Application Serial No. 08/831,823	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/904,356
		Filing Date	July 12, 2001
		First Named Inventor	G.P. Allaway
		Art Unit	1648
		Examiner Name	Jeffery S. Parkin
Sheet 37	of 47	Attorney Docket Number	43966-CB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		July 21, 1999 Final Office Action in connection with U.S. Application Serial No. 08/831,823	
		December 21, 1998 Office Action in connection with U.S. Application Serial No. 08/831,823	
		August 17, 1998 Office Action in connection with U.S. Application Serial No. 08/831,823	
		June 15, 2006 Final Office Action in connection with U.S. Application Serial No. 09/888,938	
		September 7, 2005 Office Action in connection with U.S. Application Serial No. 09/888,938	
		September 7, 2005 Office action in connection with U.S. Application Serial No. 09/888,938	
		August 4, 2004 Office Action in connection with U.S. Application Serial No. 09/888,938	
		May 5, 2004 Office Action in connection with U.S. Application Serial No. 09/888,938	
		June 22, 1999 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 08/876,078	
		December 21, 1998 Final Office Action in connection with U.S. Application Serial No. 08/876,078	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	09/904,356
Filing Date	July 12, 2001
First Named Inventor	G.P. Allaway
Art Unit	1648
Examiner Name	Jeffery S. Parkin
Attorney Docket Number	43966-CB

Sheet 38 of 47

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		March 23, 1998 Office Action in connection with U.S. Application Serial No. 08/876,078	
		June 16, 2006 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 98 931 261.6	
		June 17, 2005 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 98 931 261.6	
		October 17, 2006 Final Office Action in connection with U.S. Application Serial No. 09/460,216	
		February 3, 2006 Office Action in connection with U.S. Application Serial No. 09/460,216	
		July 29, 2005 Advisory Action in connection with U.S. Application Serial No. 09/460,216	
		February 09, 2005 Final Office Action in connection with U.S. Application Serial No. 09/460,216	
		September 26, 2003 Advisory Action in connection with U.S. Application Serial No. 09/460,216	
		February 27, 2003 Final Office Action in connection with U.S. Application Serial No. 09/460,216	
		October 2, 2001 Office Action in connection with U.S. Application Serial No. 09/460,216	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/904,356
		Filing Date	July 12, 2001
		First Named Inventor	G.P. Allaway
		Art Unit	1648
		Examiner Name	Jeffery S. Parkin
Sheet 39	of 47	Attorney Docket Number	43966-CB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		September 9, 2002 Notice of Acceptance in connection with Australian Application No. 81426/98	
		February 27, 2002 Examiner's Second Report in connection with Australian Application No. 81426/98	
		February 21, 2001 Examiner's First Report in connection with Australian Application No. 81426/98	
		February 4, 1997 Office Action in connection with U.S. Application Serial No. 08/665,090	
		August 29, 2000 Notice of Allowance and Allowability in connection with 08/874,618	
		November 19, 1999 Office Action in connection with U.S. Application Serial No. 08/874,618	
		May 24, 1999 Final Office Action in connection with U.S. Application Serial No. 08/874,618	
		September 2, 1998 Office Action in connection with U.S. Application Serial No. 08/874,618	
		December 13, 2005 Final Office Action in connection with U.S. Application Serial No. 09/724,105	
		March 23, 2005 Office Action in connection with U.S. Application Serial No. 09/724,105	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	09/904,356		
		Filing Date	July 12, 2001		
		First Named Inventor	G.P. Allaway		
		Art Unit	1648		
		Examiner Name	Jeffery S. Parkin		
Sheet	40	of	47	Attorney Docket Number	43966-CB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		September 23, 2004 Office Action in connection with U.S. Application Serial No. 09/724,105	
		May 19, 2004 Office Action in connection with U.S. Application Serial No. 09/724,105	
		December 19, 2006 Office Action in connection with U.S. Application Serial No. 11/400,497	
		August 8, 2006 Office Action in connection with U.S. Application Serial No. 11/400,497	
		May 29, 2001 Notice of Acceptance in connection with Australian Application No. 34026/97	
		September 28, 1999 Examiner's First Report in connection with Australian Application No. 34026/97	
		November 10, 2006 Official Action in connection with Canadian Application No. 2,257,991	
		May 23, 2005 Communications Pursuant to Article 96(2) EPC in connection with European Application No. 97 930 120.7	
		November 17, 2004 Communication of partial European search report under Rule 45 EPC in connection with European Application No. 97 930 120.7	
		September 9, 2004 Communication of partial European search report under Rule 46(1) EPC in connection with European Application No. 97 930 120.7	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/904,356
		Filing Date	July 12, 2001
		First Named Inventor	G.P. Allaway
		Art Unit	1648
		Examiner Name	Jeffery S. Parkin
Sheet 41	of 47	Attorney Docket Number 43966-CB	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		October 17, 2006 Notification of Reasons for Rejection in connection with Japanese Application No. 501895/98 (English translation)	
		April 5, 2004 Notice of Acceptance in connection with Australian Application No. 21996/00	
		February 5, 2003 Examiner's First Report in connection with Australian Application No. 21996/00	
		March 29, 2006 Examiner's First Report in connection with Australian Application No. 20004205164	
		March 29, 2006 Examiner's First Report in connection with Australian Application No. 20004205165	
		March 1, 2006 Communication under Rule 51(4) EPC in connection with European Application No. 99 966 466.7	
		January 10, 2005 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 99 966 466.7	
		October 14, 2004 Communication Pursuant to Article 96(1) and Rule 51(1) EPC in connection with European Application No. 99 966 466.7	
		January 18, 2007 Office communication in connection with Mexican Application No. 1006097	
		October 13, 2005 Office communication in connection with Mexican Application No. 1006097	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	09/904,356
		Filing Date	July 12, 2001
		First Named Inventor	G.P. Allaway
		Art Unit	1648
		Examiner Name	Jeffery S. Parkin
Sheet 42	of 47	Attorney Docket Number	43966-CB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		February 6, 2007 Notice of Allowability in connection with U.S. Application Serial No. 09/464,902	
		January 8, 2007 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/464,902	
		April 19, 2006 Office Action in connection with U.S. Application Serial No. 09/464,902	
		October 21, 2005 Office Action in connection with U.S. Application Serial No. 09/464,902	
		June 15, 2005 Advisory Action in connection with U.S. Application Serial No. 09/464,902	
		January 13, 2005 Final Office Action in connection with U.S. Application Serial No. 09/464,902	
		April 2, 2004 Office Action in connection with U.S. Application Serial No. 09/464,902	
		October 21, 2003 Office Action in connection with U.S. Application Serial No. 09/464,902	
		September 25, 2001 Office Action in connection with U.S. Application Serial No. 09/464,902	
		August 7, 2006 Office Action in connection with U.S. Application Serial No. 09/594,983	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/904,356
		Filing Date	July 12, 2001
		First Named Inventor	G.P. Allaway
		Art Unit	1648
		Examiner Name	Jeffery S. Parkin
Sheet 43	of 47	Attorney Docket Number	43966-CB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		March 24, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/594,983	
		July 11, 2005 Final Office Action in connection with U.S. Application Serial No. 09/594,983	
		August 25, 2004 Office Action in connection with U.S. Application Serial No. 09/594,983	
		September 23, 2003 Notice of Allowability in connection with U.S. Application Serial No. 09/594,983	
		December 3, 2002 Final Office Action in connection with U.S. Application Serial No. 09/594,983	
		March 13, 2002 Office Action in connection with U.S. Application Serial No. 09/594,983	
		September 28, 2001 Office Action in connection with U.S. Application Serial No. 09/594,983	
		December 19, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 10/763,545	
		July 26, 2006 Office Action in connection with U.S. Application Serial No. 10/763,545	
		June 13, 2006 Office Action in connection with U.S. Application Serial No. 10/763,545	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/904,356
		Filing Date	July 12, 2001
		First Named Inventor	G.P. Allaway
		Art Unit	1648
		Examiner Name	Jeffery S. Parkin
Sheet 44	of 47	Attorney Docket Number	43966-CB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		February 16, 2006 Office Action in connection with U.S. Application Serial No. 10/763,545	
		September 5, 2006 Communication in connection with U.S. Application Serial No. 10/371,483	
		August 21, 2006 Communication in connection with U.S. Application Serial No. 10/371,483	
		May 16, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 10/371,483	
		October 24, 2006 Office Action in connection with U.S. Application Serial No. 10/371,483	
		January 29, 2007 Examiner's First Report in connection Australian Application No. 2003217674	
		February 22, 2007 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 03 713 632.2	
		October 12, 2004 Communication Pursuant to Rules 109 and 110 EPC in connection with European Application No. 03 713 632.2	
		March 14, 2006 Examination Report in connection with New Zealand Application No. 534947	
		February 21, 2003 Official Action in connection with Russian Federation Application No. 2004128252/13(030609) (English Translation)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/904,356
		Filing Date	July 12, 2001
		First Named Inventor	G.P. Allaway
		Art Unit	1648
		Examiner Name	Jeffery S. Parkin
Sheet 45	of 47	Attorney Docket Number	43966-CB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		September 29, 2006 Grant of Patent in connection with Singaporean Application No. 200404610-8	
		August 7, 2002 Office Action in connection with U.S. Application Serial No. 09/663,219	
		January 5, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/912,824	
		January 26, 2005 Final Office Action in connection with U.S. Application Serial No. 09/912,824	
		April 20, 2004 Office Action in connection with U.S. Application Serial No. 09/912,824	
		July 2, 2003 Office Action in connection with U.S. Application Serial No. 09/912,824	
		July 3, 2006 Notice of Acceptance in connection with Australian Application No. 2001290925	
		June 28, 2005 Examiner's First Report in connection with Australian Application No. 2001290925	
		May 24, 2006 Supplementary European search report under Article 157(2)(a) EPC in connection with European Application No. 01970984.9	
		February 28, 2005 Formalities Examination in connection with European Application No. 01970984.9	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	09/904,356
		Filing Date	July 12, 2001
		First Named Inventor	G.P. Allaway
		Art Unit	1648
		Examiner Name	Jeffery S. Parkin
Sheet 46	of 47	Attorney Docket Number	43966-CB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		May 2, 2003 Communication Pursuant to Rules 109 and 110 EPC in connection with European Application No. 01970984.9	
		October 25, 2005 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/828,615	
		September 13, 2005 Office Action in connection with U.S. Application Serial No. 09/828,615	
		March 2, 2005 Office Action in connection with U.S. Application Serial No. 09/828,615	
		September 17, 2004 Final Office Action in connection with U.S. Application Serial No. 09/828,615	
		February 23, 2004 Office Action in connection with U.S. Application Serial No. 09/828,615	
		September 9, 2003 Advisory Action in connection with U.S. Application Serial No. 09/828,615	
		February 21, 2003 Final Office Action in connection with U.S. Application Serial No. 09/828,615	
		June 25, 2002 Office Action in connection with U.S. Application Serial No. 09/828,615	
		June 9, 2005 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 10/116,797	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/904,356
		Filing Date	July 12, 2001
		First Named Inventor	G.P. Allaway
		Art Unit	1648
		Examiner Name	Jeffery S. Parkin
Sheet 47	of 47	Attorney Docket Number	43966-CB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		April 25, 2005 Final Office Action in connection with U.S. Application Serial No. 10/116,797	
		October 6, 2004 Office Action in connection with U.S. Application Serial No. 10/116,	
		September 7, 2005 Office Action in connection with U.S. Application Serial No. 09/888,938	
		Bieniasz, P.D., et al. (1997). HIV-1 Induced Cell Fusion Is Mediated By Multiple Regions Within Both The Viral Envelope And The CCR5 Co-Receptor. EMBO, 16:2599-2609	
		Blanpain, C., et al. (1999). Multiple Charged And Aromatic Residues In CCR5... In High Affinity Binding Of Both Chemokines And HIV-1.... J. Biol. Chem., 274:34719-34727	
		February 15, 1996 Advisory Action in connection with U.S. Application Serial No. 08/169,311	
		September 13, 1995 Final Office Action in connection with U.S. Application Serial No. 08/169,311	
		November 23, 1994 Office Action in connection with U.S. Application Serial No. 08/169,311	
		August 18, 1994 Office Action in connection with U.S. Application Serial No. 08/169,311	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.